India · English
Stanford blood cancer transplant therapy reaches first commercial patient
In a remarkable advancement, Stanford researchers have unveiled Orca-T therapy, which has recently received FDA approval. After two decades of rigorous development, this innovative treatment was administered to its inaugural commercial patient, a high-risk leukemia sufferer. Notably, Orca-T significantly minimizes the chances of graft-versus-host disease post-stem cell transplants, offering…
Read the full report at Times of India Top →
About this page
AKHBAARI groups the same story across publishers so you can see who is reporting it and how they differ. The summary above is machine-generated from the publisher's own feed text and is labelled as such. The full report stays with the publisher, who holds copyright in it. See our editorial policy.